pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$IRONDisc Medicine, Inc.

$IRON83.20+4.13%
Watertown, MA, USupdated 19d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 2: 3
3Phase 2
Phase 2
MWTx-01
Polycythemia Vera
Phase 2
bitopertin
Anemia
Sodium- and chloride-dependent glycine transporter 1
Phase 2
selcodebart
Anemia

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemiarecruitingn=150
  • phase3HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLPenrolling by invitationn=230
  • phase2Study of DISC-0974-201 in Participants With IBD and Anemiarecruitingn=21
  • phase3Study of Bitopertin in Participants With EPP or XLP (APOLLO)active not recruitingn=183
  • —Expanded Access Program of Bitopertin For Participants With EPP or XLPavailable
  • phase1A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)recruitingn=24
  • phase1Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemiacompletedn=55
  • phase2A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)recruitingn=60
🐶 Hiring Signal
19 open roles at Disc Medicine, Inc. →

Where Disc Medicine, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaHematology 18Rare Disease 1
departmentMedical Affairs 7Commercial 4R&D / Discovery 4Market Access 2Business Development & Sales 1Legal & Compliance 1

News

  • STAT+: As more doctors consult chatbots, health systems can block them — or buy in
    As hundreds of thousands of doctors consult AI chatbots to make care decisions, health systems see new risks to patients' health data.
    stat · 12d ago
  • Top health takeaways from the midterm elections
    Democrats gained control of both chambers of Congress, and doctors and scientists won key seats. Here are the top health takeaways from the midterms.
    stat · 12d ago
  • STAT+: Amid Mass General Brigham layoffs, CEO pens vague letter, stirring staff anxiety
    A cryptic email sent to Mass General Brigham employees by the health system's CEO is stirring staff anxiety less than two weeks after a round of layoffs.
    stat · 13d ago
  • Politicians have failed to tackle health care affordability. It’s now voters’ rallying cry
    As costs surge, voters are embracing more radical solutions to the crisis.
    stat · 19d ago
  • Opinion: Health care needs buyers willing to say no
    "The industry’s major players have little appetite for change," writes Anthony T. Lo Sasso.
    stat · 19d ago
  • What has actually caused the decline in drug overdose deaths?
    After years of steep increases, especially amid the pandemic, U.S. overdose deaths decreased 27% in 2024, and preliminary data from 2025 show another meaningful drop.
    stat · 19d ago
  • Have you been impacted by Epic’s actions?
    STAT is looking to learn, from people with direct knowledge, how Epic's actions impact hospitals' technology choices. Share your story with us.
    stat · 20d ago
  • STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technology
    A STAT investigation found that Epic selectively withholds access to patient data, disadvantaging rival software developers and stymying innovation.
    stat · 20d ago
  • The 4 stages of women’s heart health: New framework for doctors and patients
    New guidance is intended to help girls and women — and their doctors — recognize four distinct phases in heart health.
    stat · 22d ago
  • Disc’s once-spurned rare disease drug to get a second chance at approval
    Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.
    biopharma_dive · 28d ago
view all news mentions →
identifiers
ticker
$IRON
SEC CIK
0001816736
country
US
source
sec_tickers
top tags
Oncology1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 31m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?